Introduction
Spi-1/PU.1 is a member of the ets family of transcription factors that is expressed specifically in hematopoietic tissues. spi-1/pu.1 gene disruption results in lethality (Scott et al., 1994) . It is essential for controlling the balance between self-renewal and differentiation in hematopoietic progenitor cells, and functions in a concentration-dependent manner to promote differentiation of the lymphoid and myeloid lineages (Back et al., 2004; Fisher et al., 2004 and references therein) . Furthermore, Spi-1/PU.1 is expressed at low levels in erythroid progenitor cells and subsequently downregulated on terminal differentiation. It acts to maintain the self-renewal capacity of immature erythroid precursors and to prevent differentiation in the erythroid lineage (Back et al., 2004; Fisher et al., 2004) .
Spi-1/PU.1 was initially discovered as a proviral integration site in Friend virus-induced erythroleukemia (reviewed in Moreau-Gachelin, 2008) . Friend virus complex consists of two viruses, a helper replicationcompetent Friend murine leukemia virus (F-MuLV) and a replication-defective spleen focus-forming virus (SFFV). Friend SFFV carries a unique env gene encoding a truncated form of a retroviral envelope glycoprotein (gp55), which is responsible for its pathogenicity (reviewed in Moreau-Gachelin, 2008) . In the first stage of the disease, gp55 binds and activates the erythropoietin receptor (Epo-R) and a short form of the receptor tyrosine kinase, resulting in constitutive activation of signal transducing molecules and the development of Epo-independent erythroid hyperplasia and polycythemia, due to the polyclonal expansion and differentiation of erythroid cells in the absence of Epo. The second stage of the disease results from the outgrowth of Friend SFFV-infected erythroid cells that have become transformed because of integration of the virus into the Spi-1 locus. This event triggers aberrant overexpression of the Spi-1/PU.1 protein in erythroid cells and causes a block in their differentiation and the outgrowth of transformed mouse erythroleukemia (MEL) cells (Moreau-Gachelin et al., 1989; Paul et al., 1991; Schuetze et al., 1992) . Treatment of the cells with polar compounds, such as dimethylsulfoxide (DMSO) and hexamethylene bisacetamide, causes them to reenter a differentiation program best characterized by rapid downregulation of Spi-1/PU.1 and the concomitent accumulation of hemoglobin and other membrane erythrocyte-specific proteins (reviewed in MoreauGachelin, 2008) . Consistently, forced expression of Spi-1/PU.1 blocks MEL cell differentiation (Rao et al., 1997) , and results in inhibition of growth and differentiation and apoptotic death of other erythroleukemia cell lines (Yamada et al., 1997) .
Binding of Epo to its receptor triggers the phosphorylation and activation of Epo-R-bound Janus kinase 2 (JAK2) tyrosine kinase, resulting in activation of several downstream signaling pathways that include the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB or AKT), the signal transducer and activator of transcription 5 (STAT5)-Bcl-XL and the extracellular signal-regulated kinase/mitogen-activated protein kinase (reviewed in Ghaffari et al., 2003) . In human erythroid progenitors, PI3K activation protects the cells from apoptosis and mediates Epo-induced proliferation through downregulation of p25Kip1 expression (Bouscary et al., 2003) . Activation of AKT serine threonine kinase of PKB family is crucial for Epo-induced erythropoiesis (Myklebust et al., 2002; Bouscary et al., 2003 and references therein) . This activation is mediated by PI3K through phosphorylation of Ser473 on AKT. In this context of Epo signaling, AKT is a major effector downstream of PI3K, having fundamental roles in the regulation of cell cycle, survival and differentiation (Bao et al., 1999; Bouscary et al., 2003) . Moreover, AKT activation has been reported in SFFV-infected erythroleukemic cells, in which Epo-R is constitutively activated by the viral gp55 (Nishigaki et al., 2000) . In fact, most of the signal transduction pathways induced in erythroid cells by Epo, including the Jak-STAT pathway, are constitutively activated in SFFV-transformed cells in the absence of Epo (Nishigaki et al., 2006 and references therein) . Proliferation of Epo-independent proerythroblastic cells (called HS2 cells), derived from transgenic mice overexpressing Spi-1/ PU.1, requires active PI3K/AKT and mitogen-activated protein kinase pathways (Barnache et al., 2001) . Consistently, Epo initiates a transcriptional program that leads to significant change of expression levels in over 580 genes, the majority of which are apparently regulated in a PI3K-dependent manner (Sivertsen et al., 2006) .
The inclusion of exon 16 in mature protein 4.1R mRNA is probably the best-studied example of stagespecific pre-mRNA splicing that characterizes the late erythroid development. It has been well documented that exon 16 is excluded in early erythroid progenitors and included in late erythroid differentiated cells (Chasis et al., 1993; Baklouti et al., 1996) . This regulated splicing event underlies the production of a functional 4.1R; inclusion of the 21 amino acid peptide encoded by exon 16, at the N-terminus of the 10 kDa spectrin/actinbinding domain of 4.1R is indeed essential to promote high mechanical stability and high deformability of the mature red cell membrane. We have shown that Epononresponsive MEL cells reproduce exon 16-regulated splicing on DMSO induction to erythroid differentiation from either the endogenous pre-mRNA or transfected minigene transcript (Deguillien et al., 2001) . More recently, we have observed that Eporesponsive erythroleukemia cells also efficiently regulate this splicing event when induced in culture with either DMSO or Epo (The´oleyre et al., 2004) . Exon 16 splicing is tightly correlated with Spi-1/PU.1 expression, that is, upregulated Spi-1/PU.1 in proliferative MEL cells as well as forced expression of Spi-1/PU.1 inhibit exon 16 inclusion (The´oleyre et al., 2004) . DMSO-induced or short hairpin RNA-mediated downregulation of Spi-1/ PU.1 release the inhibition and lead to exon 16 inclusion (Blaybel et al., 2008) .
For many years, great effort has been made to understand how signals received by cells impact transcription factor activity. In an attempt to connect the splicing event and its blocking by upregulated Spi-1/ PU.1 with the signaling pathways activated in MEL cells, we here provide the first direct evidence for an Epo-generated signal that modulates an erythroidspecific splicing. Our results show that constitutive PI3K/AKT sustains Spi-1/PU.1 autoregulated expression that inhibits protein 4.1R exon 16 splicing and erythroid differentiation, as evidenced by impaired globin gene expression. Inhibition of PI3K/AKT signaling blocks Spi-1/PU.1 autoregulation loop, and induces cell differentiation and 4.1R erythroid splicing activation. However, mutational targeting of specific serine residues of Spi-1/PU.1 led to uncouple the two Spi-1/ PU.1 inhibitory effects on 4.1R splicing and globin gene expression. Taking together, these data show subtle differential effects of Spi-1/PU.1 expression on late erythroid-regulated events.
Results
PI3K/AKT inhibition triggers erythroleukemia cell differentiation in the absence of DMSO Phosphatidylinositol 3-kinase complex is a protein dimer that consists of a p85 regulatory subunit and a p110 catalytic subunit. Earlier works have shown that p85 expression, phosphorylation and activity decline in Friend cells after DMSO exposure for 96 h (Bavelloni et al., 2000; Cataldi et al., 2000) . Immunoblot analysis of p85 subunit shows a reduction of the phosphorylated form of p85 (P-p85) when the cells are treated with 10-20 mM LY294002 or DMSO (Figure 1a) . Activation of PI3K triggers the phosphorylation of its downstream target AKT. As shown in Figure 1b , the phosphorylated AKT (Ser473) decreases on LY294002 treatment in a dose-dependent manner, suggesting that LY294002 is effective on both PI3K autophosphorylation and downstream AKT phosphorylation.
We then tested the effect of PI3K/AKT inhibition on MEL SFFV cells. Cells were seeded at stationary phase in the presence of increasing concentrations of LY294002, within a nontoxic range, and cell differentiation was monitored 96 h after exposure to the inhibitor. This experiment reproducibly revealed that LY294002 triggers MEL cell differentiation in a concentration-dependent manner (Figure 1c) , that is, at a 5 mM concentration, B12% of the cells were benzidine positive, whereas at a 20 mM concentration, this percentage was over 65%. In the same sets of experiments, the proportion of differentiating cells was higher, B78%, when the cells were induced to differentiate with 1.8% DMSO.
These results evidence that inhibition of the constitutive PI3K/AKT signaling triggers Friend eythroleukemia cell differentiation in the absence of DMSO chemical induction.
PI3K/AKT signaling inhibits protein 4.1R exon 16 erythroid splicing In a recent work, we have provided evidence that induction of differentiation of MEL SFFV cells triggers a transcription event (globin gene activation) and a splicing event (4.1R exon 16 inclusion) through different pathways (Blaybel et al., 2008) . These events are probably the best-characterized transcription and splicing events that label the late stage of erythroid differentiation. We asked whether PI3K/AKT signaling inhibition impacts both of these regulated events. In new sets of experiments, MEL SFFV cells were either left untreated or treated with 10 or 20 mM LY294002 for 4 days, as described above, and exon 16 splicing was analyzed by semiquantitative reverse transcriptase-PCR (RT-PCR). As outlined in Figure 2 , inhibition of the constitutive PI3K/AKT signaling results in the activation of 4.1R exon 16 splicing, again in an inhibitor dosedependent manner. However, in keeping with the effect observed on hemoglobin production, treatment with LY294002 inhibitor seems to have a less conspicuous effect on exon 16 inclusion than DMSO. Similar data were obtained using Epo-responsive cells (Friend erythroleukemia SFFV SKT6 cells and Rauscher cells) (not shown), indicating that PI3K/AKT signaling inhibits erythroleukemia cell differentiation, regardless of the Epo responsiveness of the cell line.
Collectively, these observations suggest that inhibition of the constitutive PI3K/AKT signaling alone promotes both globin gene transcription and erythroid-specific splicing of 4.1R exon 16 in erythroleukemia cells, in the absence of DMSO or Epo induction of differentiation.
Inhibition of PI3K/AKT signaling downregulates Spi-1/PU.1 expression in a stepwise manner Upregulated Spi-1/PU.1 in Friend cells inhibits globin gene transcription and blocks 4.1R pre-mRNA erythroid splicing (The´oleyre et al., 2004) . We tested Spi-1/ PU.1 expression in cells treated with PI3K/AKT inhibitor LY294002. Immunoblot analysis of Spi-1/ PU.1 expression revealed two or three isoforms with apparent molecular weights ranging within 35-37 kDa, that represent different phosphorylated forms of Spi-1/ PU.1 (Delgado et al., 1994) . As shown in Figure 3a , the PI3K/AKT induces PU.1 autoregulation loop O Breig et al unphosphorylated Spi-1/PU.1 appears unaltered up to a concentration of 15 mM of LY294002, and subsequently declines at a higher concentration (20 mM). Most remarkably, the phosphorylated forms of Spi-1/PU.1 steadily decreased as the dose of LY294002 increased, starting from as low as 5 mM.
We asked whether Spi-1/PU.1 downregulation occurs at the protein level or rather at the mRNA level. To address this issue, we examined Spi-1/PU.1 mRNA accumulation during LY294002 inhibition of PI3K/ AKT signaling, using real-time RT-PCR. This experiment clearly revealed a decrease in mRNA level that coincides with the decrease observed at the protein level for the same LY294002 concentrations (Figure 3b ).
Spi-1/PU.1 has been described to activate its own gene in myeloid cells by binding an ets sequence at þ 20 of the transcription start site (Chen et al., 1995) . We examined the Spi-1/PU.1 transcription factor occupancy at the þ 20 ets site by chromatin immunoprecipitation (ChIP) assay, using anti-Spi-1/PU.1 antibody. DNA recovered from the immune complexes was analyzed by quantitative PCR using primers surrounding the þ 20 site. As shown in Figure 4 , the ChIP experiment revealed that Spi-1/PU.1 occupancy of the þ 20 ets site is more efficient than that of a nonspecific protein.
These data suggest that inhibition of the PI3K/AKT signaling triggers a stepwise downregulation of Spi-1/ PU.1, and that PI3K/AKT-mediated phosphorylation of Spi-1/PU.1 is needed for its transactivation property, including the transactivation of spi-1/pu.1 gene itself, through a positive feedback loop.
Inhibition of PI3K/AKT is insufficient to activate 4.1R erythroid splicing in cells overexpressing Spi-1/PU.1 We next asked whether PI3K/AKT inhibits cell differentiation through a stricto sensu Spi-1/PU.1 upregulation or rather through a phosphorylation-activated form of Spi-1/PU.1. To address this issue, wild-type Spi-1/ PU.1 was overexpressed in MEL cells, under the control of heterologous promoters, and stably transfected clones were selected. One clone expressing a low level (l-PU.1 þ clone) and one clone expressing a high level (h-PU.1 þ clone) of Spi-1/PU.1 were subsequently analyzed for their ability to respond to PI3K/AKT inhibition. The generated MEL cell clones were exposed to DMSO or 20 mM LY294002. Untransfected cells again showed a shut-off of Spi-1/PU.1 on exposure to DMSO and a concentration-dependent downregulation on LY294002 exposure (Figure 5a ). Constitutive low expression of Spi-1/PU.1 was detected in l-PU.1 þ cells, and much stronger Spi-1/PU.1 signals were revealed in h-PU.1 þ cells, cultured in the same conditions (Figure 5a ). Hemoglobin synthesis was impaired in the two cell lines overexpressing Spi-1/PU.1, even after DMSO treatment. Interestingly, PI3K/AKT inhibition induced hemoglobin synthesis in l-PU.1 þ cells. Conversely, h-PU.1 þ culture exposed to 20 mM LY294002 produced only few, if any, benzidine-positive cells. In total, a converse relationship between the level of expressed Spi-1/PU.1 and the percentage of benzidinepositive cells (72% in untransfected cells, 40% in l-PU.1 þ cells and 3% in h-PU.1 þ cells) is observed, suggesting a titration effect between Spi-1/PU.1 quantitative level and its phosphorylation level (Figure 5a ). 1( þ 20) ) was explored for Spi-1/PU.1 protein binding. DNA-protein complexes were immunoprecipitated using either anti-Spi-1/PU.1 antibody or a nonspecific anti-p27 antibody. Immunoprecipitated DNA fragments were amplified using primers specific for each gene promoter/enhancer. GAPDH, 129k and 153k were used as negative controls. Nip7 served as a positive control for Spi-1/PU.1 binding (Juban et al., 2009) . Data are expressed as site occupancy normalized against GAPDH background DNA-protein association.
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Moreover, western blot analysis revealed only a partial inhibition of Spi-1/PU.1 phosphorylation in cells overexpressing Spi-1/PU.1 (Figure 5a ), which argues in favor of a titration effect on LY294002-mediated PI3K/AKT inhibition. Interestingly, exon 16 splicing was also modulated in these cells; as expected, exon inclusion was inhibited in DMSO-treated cells overexpressing Spi-1/PU.1, but not in untransfected or mock-transfected cells (Figure 5b) . However, inhibition of PI3K/AKT induced the activation of exon splicing in untransfected and mock-transfected cells, but not in cells overexpressing Spi-1/PU.1 (Figure 5b) .
Collectively, these experiments provide evidence that Spi-1/PU.1 inhibits both late erythroid transcriptional and splicing events in a phosphorylation-dependent manner. Exon 16 remains massively excluded in LY294002-treated cells. We anticipate that Spi-1/PU.1 inhibits exon 16 splicing in these conditions through (i) its unphosphorylated form, expressed from the transfected Spi-1/PU.1 cDNA, (ii) residual Spi-1/PU.1 phosphorylated forms, that remain active at 20 mM LY294002 concentration or/and (iii) a PI3K/AKTindependent phosphorylation of Spi-1/PU.1.
Distinct effects of phosphorylated Ser residues on Spi-1/PU.1 role in globin gene expression and 4.1R erythroid splicing Spi-1/PU.1 is phosphorylated on multiple serine residues in its transactivation and PEST regions (Pongubala et al., 1993) . In particular, phosphorylation of Spi-1/ PU.1 on Ser148 by casein kinase II controls the recruitment of B-cell-specific factors, such as NF-EM5 and Pip, on the kE3 0 and lB enhancers, leading to an increase of the transcriptional activity of Spi-1/PU.1 (Pongubala et al., 1993; Eisenbeis et al., 1995) . It has also been evidenced that AKT stimulation of Spi-1/PU.1 is due to phosphorylation within the transactivation domain at amino acid residue Ser41. Mutation of serine 41 to alanine (S41A) impaired Spi-1/PU.1 induction by AKT signal (Rieske and Pongubala, 2001) .
We asked whether Spi-1/PU.1 requires either or both of these sites for repression of the transcription and the splicing events. Wild-type Spi-1/PU.1 and mutants containing serine to alanine mutations at positions 41 and 148 were generated and transfected as enhanced green fluorescent protein (EGFP) fusions in MEL SFFV cells. Cells were cultured in the presence or absence of DMSO. Immunoblot analysis using anti-Spi-1/PU.1 The exon inclusion is enhanced in untransfected cells and in mock cells on exposure to either DMSO or LY294002. In cells overexpressing Spi-1/PU.1, the exon is roughly excluded in all conditions, suggesting that LY294002-mediated inhibition of Spi-1/PU.1 phosphorylation is insufficient to repress exon inclusion.
antibody ascertained the high expression of EGFPSpi-1/PU.1 fusion proteins, which is maintained after DMSO exposure, whereas the endogenous Spi-1/PU.1 dramatically decreases in all cell clones, on DMSO induction (Figure 6a ). Expression of wild-type Spi-1/ PU.1 and mutant S148A impaired hemoglobin synthesis, whereas that of mutant S41A resulted in about 40% of hemoglobin producing cells after DMSO treatment (Figures 6a and b) . These results suggest that phosphorylation at Ser41 residue, but not at Ser148, is required for Spi-1/PU.1 transcriptional activity as a globin gene repressor. However, expression of S41A or S148A Spi-1/PU.1 mutants failed to inhibit exon inclusion (Figure 6c ). These data show that Spi-1/PU.1 phosphorylation-mediated modifications, both within the transactivation domain and the PEST domain, are required for the inhibitory effect of Spi-1/PU.1 on exon 16 erythroid splicing.
Collectively, these experiments provide evidence that distinct Spi-1/PU.1 phosphorylation-mediated modifications direct specific inhibitions of late erythroid molecular events.
Discussion
PI3K/AKT-mediated phosphorylation of Spi-1/PU.1 sustains a high level of expression of Spi-1/PU.1 through an autoregulatory loop The signaling events initiated by the binding of Epo to the Epo-R induce proliferation, survival and differentiation of erythroid progenitors (Jelkmann, 2007) . Most Friend erythroleukemia cell lines display an SFFV provirus integrated in a reverse orientation relative to the Spi-1/PU.1 promoter. This observation led to the hypothesis that enhancer elements present in the long terminal repeat of SFFV activate Spi-1/PU.1 transcription; however, direct experimental evidence for this model is still lacking (Moreau-Gachelin, 2008) . In Friend erythroleukemia, it has been anticipated that in the early preleukemic stage, the Spi-1/PU.1 promoter may be activated in a Spi-1/PU.1-independent manner by an Epo-R/F-gp55 signal. Hereafter, cell clones with integrated SFFV provirus in the spi-1/pu.1 gene locus expand and display high level of Spi-1/PU.1, involving the activation of spi-1/pu.1 gene transcription by an enhancer element present in the SFFV long terminal repeat (Moreau-Gachelin et al., 1989; Okuno et al., 2005) . High levels of Spi-1/PU.1 protein are necessary to maintain the transformed phenotype (Afrikanova et al., 2002) .
Here, we identified the PI3K/AKT pathway as a mediator of Spi-1/PU.1 autoregulatory loop that maintains Spi-1/PU.1 in a phosphorylated form capable to transactivate its own gene. Data gathered from previous works and data presented here, altogether suggest that activation of Spi-1/PU.1 in MEL cells implies a two-step regulatory mechanism, whereby SFFV gp55 glycoprotein first binds and activates Epo-R, which leads to constitutive activation of PI3K/AKT signaling. Active PI3K/AKT subsequently mediates Spi-1/PU.1 phosphorylation and therefore triggers a constitutive activation of spi-1/pu.1 gene through a positive feedback loop. This autoregulatory mechanism sustains a high level of expression of Spi-1/PU.1, responsible for blocking erythroid differentiation. Inihibition of PI3K/AKT blocks PI3K/AKT-mediated phosphorylation of Spi-1/PU.1 and subsequently inactivates Spi-1/PU.1-mediated autoregulation. Supportive of this model is the observation that Epo-R activation of SFFV by the env gene leads to transcriptional upregulation of Spi-1/PU.1 in the absence of Epo and in the absence of an integrated SFFV provirus within the Spi-1/PU.1 locus (Afrikanova et al., 2002) .
Spi-1/PU.1 inhibits hemoglobin synthesis in a PI3K/AKT-dependent manner Here, we show that specific inhibition of PI3K/AKT is sufficient to induce hemoglobin synthesis. Nonetheless, a previous work has shown that LY294002 inhibition of PI3K/AKT signaling prevents differentiation of MEL cells (Bavelloni et al., 2000) . This apparent contradiction might be due to the fact that in the majority of our experiments, we used either DMSO or 10-20 mM LY294002, whereas in early works, cells were treated using 0.1-10 mM LY294002 concomitantly with DMSO (Bavelloni et al., 2000; Cataldi et al., 2000) . By constitutively overexpressing Spi-1/PU.1 at different levels in MEL cells, we were able to show that Spi-1/ PU.1 protein level can titrate the inhibitory effect of LY294002 ( Figure 5) , and therefore the inhibition efficiency of the PI3K/AKT signaling depends on the balance between Spi-1/PU.1 expression level and the concentration of LY294002 inhibitor. The possibility remains that use of different MEL cell clones, 707 clone (Bavelloni et al., 2000) versus 745-A clone (this work), might account for the apparent conflicted results. However, we did observe similar effects of PI3K/AKT inhibition in SKT6 and Rauscher erythroleukemia cells (data not shown).
We also found that PI3K/AKT phosphorylation of Spi-1/PU.1 is responsible for its role in blocking erythroid differentiation of MEL cells and more specifically in hemoglobin synthesis. As recapitulated in Figure 7 , the repression activity of Spi-1/PU.1 requires phosphorylation of the transactivation domain on S41 residue, but not that of the PEST domain on S148. These data are consistent with previous works addressing the transcriptional regulation of erythroid gene targets by the functional antagonism between Spi-1/PU.1 and GATA-1. This antagonism involves direct interactions between the two proteins, in which the GATA-1 C-terminal zinc finger, on one side, and both the DNA-binding and transactivation domains of Spi-1/ PU.1, on the other side, are implicated. Both of these Spi-1/PU.1 domains are also needed to block erythroid differentiation in MEL cells (Rekhtman et al., 1999; Zhang et al., 1999; Nerlov et al., 2000) .
Spi-1/PU.1 inhibits 4.1R erythroid splicing through PI3K/AKT-dependent and -independent pathways A growing attention has been focused on how cellular signals induced by growth factors, cytokines, hormones and membrane depolarization can change the splicing pattern of several pre-mRNAs (Blaustein et al., 2007; Tarn, 2007) . Recent works have provided in vitro and in vivo evidence showing that PI3K/AKT pathway regulates specific alternative splicing events through phosphorylation of selective SR proteins (Blaustein et al., 2005; Patel et al., 2005) . Here, we provide the first observation that couples a functionally critical alternative splicing event to a signaling cascade that has an essential role in Epo-induced erythropoiesis. In total, downregulation of Spi-1/PU.1, either through DMSO treatment (Schuetze et al., 1992) , short hairpin RNAmediated knockdown (Blaybel et al., 2008) or PI3K/ AKT signaling inhibition (this work), remains the key event that commits Friend erythroleukemia cells to late erythroid differentiation and induces the erythroid splicing of 4.1R exon 16.
High level of Spi-1/PU.1 expressed in proliferative MEL cells or forced expression of Spi-1/PU.1 in DMSO-induced cells prone to differentiate, result in efficient block of 4.1R exon 16 splicing (The´oleyre et al., 2004) . Results presented here indicated that Spi-1/PU.1 inhibits exon 16 splicing in a phosphorylation-dependent manner. Moreover, phosphorylation of both the transactivation and the PEST domains is important for Spi-1/PU.1 effect on splicing (Figure 7 ). These data are consistent with previous observation showing the importance of both of these domains of Spi-1/PU.1 in modulating alternative splicing events within an exogenous pre-mRNA template (Delva et al., 2004) .
The cumulative data on Epo-R signaling and Spi-1/ PU.1 deregulation in MEL cells and the impacts on transcriptional and splicing targets, suggest a coordinated stage-specific sequence of events that are initiated by constitutive activation of Epo-R and its downstream signaling pathways. The distinct effects of Spi-1/PU.1 phosphorylation on globin gene transcription and 4.1R exon 16 splicing suggest the presence of two inhibitory pathways of late erythroid differentiation; one of which is PI3K/AKT-dependent, involves Ser41 and acts on Spi-1/PU.1 transcriptional activity, including the activation of its own gene. The other pathway is PI3K/AKTindependent, and involves Ser148. Both signaling cascades, however, are required for 4.1R exon 16 splicing inhibition in proliferative MEL cells (Figure 7 ). These observations further fuel the concept that we have proposed of two different Spi-1/PU.1-mediated pathways contributing to exon 16 exclusion (Blaybel et al., 2008) .
Materials and methods

Plasmid constructs
We generated recombinant plasmids expressing different levels of Spi-1/PU.1 on MEL cell stable transfection. For low Spi-1/ PU.1 expression, we used the previously described pHOOKSpi-1 construct (The´oleyre et al., 2004) ; the cell clone will be On the other hand, phosphorylation on serine residue 148 (S148) within the PEST domain of Spi-1/PU.1 is not required for transcription repression of globin genes and, again, it is necessary, but insufficient, for inhibition of the splicing event.
PI3K/AKT induces PU.1 autoregulation loop O Breig et al referred to as 'l-PU.1 þ ' clone. For high Spi-1/PU.1 expression, we generated a new cell clone, as follows: the entire coding sequence of Spi-1/PU.1 was amplified by RT-PCR using the following forward and reverse primers: PU-S1: 5 0 -CTCTCCGGAATGTTACAGGCGTGCAAAATG-3 0 and PU-AS1: 5 0 -TGCGAATTCTCAGTGGGGCGGGAGGCGC CG-3 0 . For accurate cloning, BspEI and EcoRI restriction sites were added at the 5 0 ends of these primers, respectively (underlined region). The PCR product was inserted at the BspEI/EcoRI site of PEFbosEGFP-C1 expression vector (Sanjuan et al., 2001) in matched open reading frame with the EGFP. The resulting construct PEFbosEGFP-C1-PU.1 was transfected in MEL cells, and the selected clone used in this study will be referred to as 'h-PU.1 þ '.
Mutations of Spi-1/PU.1 were made by a two-step PCR approach (Maillet et al., 1996) using the wild-type construct PEFbosEGFP-C1-PU.1 as template. The first-step PCRs were performed with each of the outer primers, PU-S1 or PU-AS1, and the corresponding inner primers containing the specific mutation to be incorporated in the cDNA. The resulting PCR products were then used as templates for the second-step PCR and amplification was performed using the outer primers. The final PCR products were subcloned as BspEI/EcoRI-digested fragments in PEFbosEGFP-C1. The inserts were fully sequenced to ascertain the incorporation of the specific nucleotide changes and the absence of other changes in sequences and reading frames. The inner primer set for Spi-1/PU.1 S41A mutation was: S41A-S: 5 0 -TTCGTGGGCGCCGATGGAGA-3 0 ; S41A-AS: 5 0 -TCTCCATCGGCGCCCACGAA-3 0 . The inner primer set for S148A mutation was: S148A-S: 5 0 -CTGGAGGTGGCTGAT GGAGA-3 0 ; S148A-AS: 5 0 -TCTCCATCAGCCACCTCCAG-3 0 . The nucleotide changes are underlined.
Cell culture, induction and transfection Three erythroleukemia cell lines were used: MEL 745-A is an Epo-nonresponsive SFFV subclone, and SKT6 and Rauscher are Epo-responsive cell lines (The´oleyre et al., 2004) . Cells were grown in suspension in Iscove's modified Dulbecco's medium supplemented with 13% fetal bovine serum under standard conditions (37 1C, 5% CO2). Induction of erythroid differentiation was performed by culturing the cells for 4 days, in a fresh complete medium, supplemented with 1.8% DMSO. Inhibition of PI3K/AKT signaling was achieved by adding LY294002-specific inhibitor (Sigma Aldrich, Saint Quentin Fallavier, France) to cell culture at 5-20 mM final concentrations. Hemoglobin synthesis was assessed by the benzidine staining reaction using standard procedure (Cataldi et al., 2000) .
For stable expression, proliferative cells (2 Â 10 5 cells) were transfected with 0.5-1 mg plasmid DNA using LipofectAmine (Invitrogen, Cergy Pontoise, France) or Transfast (Promega, Charbonnie`res-Les Bains, France) compounds in 24-well tissue culture plates, according to the manufacturers procedures. Transfected cells were then seeded to limited dilutions in 96-well plates with complete IMDM medium containing 800 mg G418 per ml or 400 mg zeocin per ml, to select stably transfected clones. Individual clones were analyzed for the expression of the exogenous proteins.
Semiquantitative RT-PCR and real-time RT-PCR Total RNA was isolated using TRIZOL reagent (Invitrogen) from cell lysates according to the manufacturer's protocol. Inclusion of exon 16 in mature 4.1R mRNA was assessed by semiquantitative RT-PCR, as previously described (Deguillien et al., 2001; The´oleyre et al., 2004) .
The steady-state expression of Spi-1/PU.1 mRNA was estimated by real-time RT-PCR, using a forward primer within exon 3: 5 0 -CCGCACACCATGTCCACAAC-3 0 and a reverse primer within exon 4: 5 0 -ATCCGGGGCATGTAGGA AAC-3 0 , and a 193 bp fragment was generated. b-Actin mRNA, used as internal control, was amplified using previously described primers (Juban et al., 2009) , and a 230 bp fragment was generated. The reverse transcription step was performed on 1 mg of total RNA for 60 min at 37 1C using 0.01 mg of random hexamers, 0.125 mM of dNTP mix, 1 U of RNase inhibitor and 10 U of reverse transcriptase (Fermentas, St-Re´my les Chevreuse, France). The PCR step was performed using light cycler 480 SYBER Green I Master (Roche Applied Bioscience, Meylan, France) as follows: To 2.5 ml of 1/5 diluted RT product, 10 mM of each primer and 5 ml of PCR Mix were added in a final volume of 10 ml. A total of 45 cycles of amplification (20 s at 95 1C; 20 s at 60 1C; 15 s at 72 1C) were performed on a LightCycler MX3000P (Stratagene Agilent Technologies, Massy, France).
Western blot
Erythroleukemia cells were cultured under various treatment conditions. Whole cell lysates were prepared from these cells, fractionated on sodium dodecyl sulfate polyacrylamide gel electrophoresis and blotted onto nitrocellulose membranes. The protocols were as previously detailed (Blaybel et al., 2008) .
The membranes were probed with the following primary antibodies: anti-Spi-1/PU.1 antibodies: the first batch was a gift from Dr F Moreau-Gachelin, (Delgado et al., 1994) (1/1000), the second batch was an anti-Spi-1/PU.1 directed against the C-terminal region (1/200, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, manufactured by Tebu-Bio, Le Perray-enYvelines, France); anti-PI3K p85 subunit (1/1000, a gift from Dr Mouchiroud); anti-phospho-AKT(Ser473) antibody, specifically directed against the phosphorylated form of AKT on Ser residue 473 (1/200, Santa Cruz); anti-GFP (1/1000, Roche Applied Bioscience); anti-b-actin monoclonal antibody directed against mouse b-actin (1/10 000, Chemicon International, Temecula, CA, USA); and anti-Grb2 antibody (1/10 000, BD Transduction Laboratories). Anti-b-actin and anti-Grb2 antibodies were used to standardize proteins signals. After primary antibodies, appropriate peroxidase-conjugated secondary antibodies were used. Immunoreactive bands were revealed by ECL þ enhanced chemiluminescence reagent (Amersham Biosciences AB, Uppsala, Sweden).
ChIP assay
Chromatin immunoprecipitation experiments were performed essentially as previously detailed (Juban et al., 2009) . Briefly, MEL cells were crosslinked with 1% formaldehyde, washed with PBS and lysed in sodium dodecyl sulfate buffer. DNA was then fragmented on ice by sonication to mean lengths of about 300 bp. Complexes were immunoprecipitated overnight at 4 1C on a rotating wheel, using 3 mg of anti-Spi-1/PU.1 antibody or anti-p27 antibody (Santa Cruz). DNA fragments were recovered by proteinase K digestion and phenol-chloroform extraction. Immunoprecipitated DNA was quantified by real-time PCR using the following Spi-1/PU.1-specific primers: ChIP-S: 5 0 -GAGACTTCCTGTAGCGCAAG-3 0 ; ChIP-AS: 5 0 -TGGGTCAGACGCAGGGCTCA-3 0 .
Abbreviations
ChIP, chromatin immunoprecipitation; DMSO, dimethylsulfoxide; Epo, erythropoietin; MEL, mouse erythroleukemia; SFFV, spleen focus-forming virus.
